Sciety has led a SEK 45 million investment round in PeptiSystems to support the company's expansion and innovation in synthesis instruments for peptide and oligonucleotide-based drugs.

Target Information

PeptiSystems a pioneering life science company based in Uppsala, Sweden, specializes in the development and sale of advanced synthesis instruments aimed at enhancing the production of active pharmaceutical ingredients, particularly for peptide- and oligonucleotide-based drugs. With a robust growth trajectory, PeptiSystems has successfully expanded its customer base and is gaining international recognition for its innovative solutions. The recent investment will enable the company to fast-track its global expansion and respond to the rising demand for sophisticated pharmaceutical manufacturing technologies.

In the past year, PeptiSystems has made significant progress in its commercial development, including increased sales in the United States, the establishment of a new distribution agreement in China, and collaborations with prominent contract manufacturers in India. Additionally, the company has entered into an exclusive global partnership with Asahi Kasei Bioprocess America (AKBA) to further drive advancements in peptide synthesis. A notable achievement includes the delivery of their synthesis instrument OligoNavigator to the renowned pharmaceutical company Servier, marking a pivotal moment in PeptiSystems' international venture.

Industry Overview in Sweden

Sweden's life science industry is among the most advanced globally, recognized for its innovative research and robust healthcare infrastructure. The country has established a conducive environment for biopharmaceutical development, supported by a strong col